Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck

Reto Abele, Michel Clavel, Silvio Monfardini, Utta Bruntsch, Josette Renard, Martine Van Glabbeke, Herbert M. Pinedo

Research output: Contribution to journalArticle

Abstract

A phase II study of iproplatin was conducted in advanced squamous cell carcinoma of the head and neck both in patients previously treated with chemotherapy or not. Iproplatin was given intravenously every 4 weeks at the dose of 240-300 mg/m2 without hydration. A total of 101 4-week courses was given to 50 eligible patients. No antitumor activity was detected. Drug-induced toxicity consisted in moderate myelosuppression, frequent but mild nausea and vomiting, and occasionally diarrhea and stomatitis. This study demonstrates that iproplatin given in this dose and schedule is devoid of activity in advanced squamous cell carcinoma of the head and neck.

Original languageEnglish (US)
Pages (from-to)387-389
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number4
DOIs
StatePublished - 1987
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

  • Cite this

    Abele, R., Clavel, M., Monfardini, S., Bruntsch, U., Renard, J., Van Glabbeke, M., & Pinedo, H. M. (1987). Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck. European Journal of Cancer and Clinical Oncology, 23(4), 387-389. https://doi.org/10.1016/0277-5379(87)90374-9